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Abstract
Background: Condylomata acuminata (genital warts) is the most common sexually transmitted disease, and imiquimod
is the sole FDA-approved medication for combating this condition. Vitiligo associated with imiquimod treatment
of condylomata acuminata is rare.
Case presentation: A 28-year-old male with condylomata acuminata of the penis presented to our clinic. After
removing his condylomata acuminata, we advised him to use imiquimod 5% cream to prevent relapse. When he
presented to our clinic again about 12 weeks later, he complained of vitiligo patches on his penis and scrotum.
Physical examination showed vitiligo patches involving the glans penis, shaft of the penis, and scrotum, and
remaining pigmented areas within the plaques of vitiligo.
A skin biopsy of the dorsal surface of the penis showed a complete absence of melanocytes and melanin
granules in the basal layer; the dermis was normal.
Conclusion: This is the first report of a case of imiquimod-induced vitiligo diagnosed by histopathological
examination. This adverse effect should be considered when dermatologists prescribe this medication.
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Background
Condylomata acuminata (genital warts) is the most com-
mon sexually transmitted disease. It is caused by human
papilloma virus (HPV) infection, which may contribute
to cervical cancer [1]. The primary goals of treatment
are removal of the visible warts and prevention of recur-
rence. The many methods in the therapy of condylomata
acuminata include cryotherapy, electrodessication, CO2
laser, trichloroacetic acid, podophyllin resin 10%–25%,
and imiquimod 5% cream [2,3]. Among them, imiquimod
is the sole FDA-approved medication for combating con-
dylomata acuminata. It is also used to treat certain dis-
eases of the skin such as Bowen’s disease, common and
plantar warts, molluscum contagiosum, herpes simplex,
Paget’s disease, basal cell carcinoma, and superficial squa-
mous cell carcinoma. Although regarded as a safe drug,
mild-to-moderate, local and systemic, adverse effects of
imiquimod may occasionally occur [4]. Since vitiligo-like
hypopigmentation associated with imiquimod treatment
of condylomata acuminata was first reported by Brown
in 2005, to the best of our knowledge there have been
only eight patients with either vitiligo or vitiligo-like
hypopigmentation associated with imiquimod treatment of
condylomata acuminata described in the literature [5-11].
The clinical features of these patients are listed in Table 1.
Here, we present an unusual case of imiquimod-
induced vitiligo in a 28-year-old male, whose diagnosis
was made using clinical and histopathological methods.
Case presentation
A 28-year-old Chinese male presented to our clinic with
a 3-year history of condylomata acuminata of the penis.
His lesions had been previously treated several times
with liquid nitrogen and electrodessication without caus-
ing any pigmentary changes, but his problem had re-
lapsed half a month before presentation and now he was
presenting with five new warts. The patient was treated
with electrodessication to remove his condylomata acu-
minata. When his wound healed 12 days later, he was
advised to use imiquimod 5% cream for relapse preven-
tion. He applied the cream for three nights weekly and
washed it off in the morning. Before long, he noticed
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some irritation from erythema and excoriation in the
treated areas, but he persisted in the application. After
about 12 weeks of continuous use, he again presented to
the clinic complaining of vitiligo-like depigmentation of
the macules on his penis. He was instructed to stop
using the imiquimod, but the macules in the treated
areas gradually enlarged and asymptomatically merged; a
vitiligo-like, depigmented patch also appeared on his
scrotum during the following 10 days. After 4 weeks of
applying tacrolimus 0.1% ointment, the lesions became
slightly repigmented, and the area of vitiligo lesions sta-
bilized. Unfortunately, no further repigmentation oc-
curred after 3 months of follow-up.
Laboratory examination and a skin biopsy were rec-
ommended. He and his family members had no history
of vitiligo, other depigmented dermatoses, or auto-
immune disorders. He denied use of any other topical
treatment. Physical examination showed vitiligo patches
involving the glans penis, the shaft of the penis, and the
scrotum, along with some remaining pigmented areas
within the vitiligo plaques (Figure 1). Wood’s light ac-
centuated the depigmented areas. He was not tired or ir-
ritable. EKG, chest X-ray, and thyroid and abdominal
ultrasonic scans indicated no cardiac, pulmonary, bilat-
eral thyroid, hepatic, splenic, nephritic, or other organ
involvement.
Additional laboratory analysis revealed normal counts
of white blood cells, red blood cells and blood platelets;
normal elevated erythrocyte sedimentation rate; normal
thyroid function tests; negative antistreptolysin O titer
and rheumatoid factor; normal serum immunoglobulins
G, M, and A, E levels; normal liver enzyme level; normal
blood urea nitrogen and creatinine level; normal blood
glucose level; negative antinuclear and antineutrophil
cytoplasmic antibodies; negative HIV and syphilis anti-
bodies; normal hepatitis A, B, and C serology; normal
urine and stool analysis.
A skin biopsy was performed on the dorsal surface of the
penis, which showed a complete absence of melanocytes
and melanin granules in the basal layer but with a normal
dermis (Figure 2). Loss of melanocytes and melanin gran-
ules in the epidermis was highlighted by Fontana-Masson
staining (Figure 3). Melanocytes and melanin granules exist
in the epidermal basal-cell layer of normal skin (Figure 4).
He was diagnosed, clinically and pathologically, with
imiquimod-induced localized vitiligo.
Discussion
Imiquimod is an immune response modifier with the
chemical structure 1-(2-methylpropyl)-1H-imidazo[4,5-c]
quinolin-4-amin. Since imiquimod was authorized on the
US market in 1997 and on the Chinese market in 2003, it
has been approved as a patient-applied topical treatment
for condylomata acuminata in adults. We find it is a well-
tolerated drug but with the frequent side effects of ery-
thema, burning, blistering, and excoriation. We also noted
its other adverse effect of inducing localized vitiligo, which
occurred in the treated areas.
Vitiligo is a condition characterized by depigmentation
of the skin and mucous membranes, with well-demarcated,
depigmented macules and patches. The etiology of vitiligo
is unknown, but research suggests that it may involve auto-
immune, genetic, and other factors. Autoimmune disorders
are often associated with thyroid abnormalities, pernicious
anemia, systemic lupus erythematosus, and other diseases.
Our patient denied any family history of vitiligo or
Table 1 Comparison of published cases of imquimod-induced vitiligo or vitiligo-like depigmentation in English
literature
Case Author (year) Age (year)/
gender
Diagnosis Site Clinical presentation Pathology Family
genetic
history
1 Brown et al. 2005 [5] 25/M Vitiligo-like
hypopigmentation
Scrotum Multiple depigmented
patches on the scrotum
ranging from 3 mm to 2 cm
No No report
2 Stefanaki et al. 2006 [6] 32/M Vitiligo Dorsal surface of penis,
scrotum, and pubic area
Vitiligo, slight repigmentation No Yes
3 Senel et al. 2007 [8] 32 M Vitiligo-like
depigmentation
Glans penis, shaft of penis,
and scrotum
Depigmented areas No No
4 Al-Dujaili et al. 2007 [7] 21/M Vitiligo Penile shaft and scrotum Depigmented patches No No report
5 Serrão et al. 2008 [9] 26/M Vitiligo-like
depigmentation
Shaft of penis Vitiligo-like depigmentation No No report
6 Zhang et al. 2011 [10] 25/M Vitiligo Coronoid sulcus and
corpus penis
Ivory-white patch nearly
4 × 2 cm
No No report
7 Zhang et al. 2011 [10] 22/M Vitiligo Penis Depigmented patches with
irregular pigmented edges
No No report
8 Wang et al. 2013 [11] 36/F Vitiligo Perineum and perianal Depigmentation patches
with clear demarcation lines
No No
Li et al. BMC Infectious Diseases 2014, 14:329 Page 2 of 5
http://www.biomedcentral.com/1471-2334/14/329
autoimmune disorder, the possibility of which was ex-
cluded by laboratory analysis. He denied use of any other
topical treatments in the areas treated with imiquimod 5%
cream. The features of his depigmented patches and histo-
pathology support the diagnosis of vitiligo. Therefore, we
believe that the vitiligo patches of our patient were induced
by the imiquimod. We were able to obtain a small amount
of superficial skin from the dorsal surface of the genital le-
sions in the perineal region. All eight of the patients
reported in the English literature refused biopsies of the
depigmented areas, and one even refused to have the le-
sions photographed. Therefore, our patient is the first to
undergo histopathological examination and whose diagno-
sis was based on clinical and histopathological findings.
The possible mechanism for the destruction of the hu-
man papilloma virus (HPV) by imiquimod is that it
stimulates peripheral blood monocytes, macrophages,
and dendritic cells to produce such cytokines as inter-
feron alfa (IFN-α), interleukin-12 (IL-12), and tumor ne-
crosis factor alfa (TNF-α), so imiquimod can enhance
the host’s innate and cellular immune response and
combat anogenital HPV infection [12,13]. To study the
safety and effectiveness of imiquimod 5% cream in the
treatment of external anogenital warts, Edwards et al.
applied it on 109 patients; 50% of the patients experi-
enced eradication of all treated baseline warts [14].
Figure 1 Vitiligo patches involving the glans penis, shaft of the
penis, and scrotum after the use of imiquimod 5%. a. Vitiligo on
the patient’s penis,some remaining pigmented areas within the vitiligo.
plaques . b. vitiligo on the patient’s scrotum.
Figure 2 Loss of melanocytes and melanin granules. a. Normal
stratum corneum, stratum granulosum, and stratum spinosum, with
loss of melanocytes and melanin granules in the basal layer. Dermis
showing no abnormalities (H&E ×100). b. loss of melanocytes and
melanin granules in the basal layer (H&E ×200).
Figure 3 Absence of melanin granules. a. Absence of melanin
granules in epidermis. Normal dermis. (Masson-Fontana stain for
melanin ×100). b. Absence of melanin granules in epidermal basal
cell layer. (Masson-Fontana stain for melanin ×200).
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Other studies also indicated that imiquimod 5% cream
was effective in treating condylomata acuminata. How-
ever, imiquimod not only kills the HPV but also destroys
melanocytes. Similarly, the mechanism of imiquimod-
induced vitiligo may be that the medication activates the
Langerhans cells in the lesions via antigen presentation,
leading to the destruction and apoptosis of the melano-
cytes. Imiquimod-induced apoptosis of melanocytes was
confirmed by TUNEL assay, Hoechst 33258 staining,
and measuring mitochondrial membrane potential in me-
lanocytes [15]. Moreover, imiquimod can induce cytokines
such as IFN-α, TNF-α, IL-6, IL-8, and nitric oxide to cause
vitiligo [16]. Additionally, imiquimod binds to Toll-like
receptor-7 and −8, increasing production of proinflamma-
tory cytokines such as IFN-α, TNF-α, and LI-12 [17,18],
which play a role in the pathogenesis of vitiligo.
Accompanying the use of imiquimod on increasing
numbers of patients with condylomata acuminata, derma-
tologists should keep this potential side effect in mind.
Conclusion
Imiquimod 5% cream, as an immune response modifier
and a safe drug, is used to treat condylomata acuminata,
basal cell carcinoma, Bowen’s disease, common and plan-
tar warts, molluscum contagiosum, and other disorders.
However, mild-to-moderate, local and systemic, adverse
effects of imiquimod may occasionally occur. Among its
adverse effects, imiquimod-induced vitiligo should be an-
ticipated when dermatologists prescribe this drug.
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